Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

NSD2 is a conserved driver of metastatic prostate cancer progression.

ABSTRACT: Analysis of transcriptome of FACS isolated cancer cells from prostate primary tumors and metastasis from NPK GEM models

ORGANISM(S): Mus musculus

PROVIDER: GSE111291 | GEO | 2018/12/05

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

NSD2 is a conserved driver of metastatic prostate cancer progression.

Project description: Not available

| S-EPMC6281610 | biostudies-literature

NSD2 is a conserved driver of metastatic prostate cancer progression.

Project description:NSD2 is a conserved driver of metastatic prostate cancer progression.

| PRJNA436465 | ENA

Targeting NSD2 in mouse prostate cancer cells

Project description:Transcriptome analysis of mouse prostate cancer cell line (NPK) silenced for Nsd2 using shRNA or treated with MCTP--39. NPK prostatre cancer cells are derived Nkx3.1CreERT2/+ ;Ptenflox/flox;KrasLSL-G12D/+ mice, and were used to silence the histone methyltransferase NSD2 or treat them with the NSD2 inhibitor MCTP39 for subsequent gene expression profiling by RNAseq

2019-07-23 | GSE118784 | GEO

ETV4 promotes metastasis in response to combined activation of PI3kinase and RAS signaling in a mouse model of advanced prostate cancer

Project description:Analysis of the transcriptome of mouse models of prostate cancer. NP (Nkx3.1CreERT2/+; Ptenfloxed/floxed) mice develop non-metastatic tumors while NPK (Nkx3.1CreERT2/+; Ptenfloxed/floxed; KrasG12D/+) mice develop metastatic tumors The NPK mice are also analyzed at early and late stages of tumorigenesis (1 vs. 3 months after induction) Total RNA obtained from prostate tumors of different genotypes and at different stages of dissease as indicated

2013-07-23 | E-GEOD-47697 | biostudies-arrayexpress

ETV4 promotes metastasis in response to combined activation of PI3kinase and RAS signaling in a mouse model of advanced prostate cancer

2013-07-23 | GSE47697 | GEO

Identifying actionable targets through integrative analyses of GEM model and human prostate cancer profiling [Agilent]

Project description:Here we prolife prostate cancers derived from GEM models of prostate cancer representative of human prostate cancer Total DNA was isolated from established prostate cancers in 4 GEM models of prostate cancer - PB-MYC, Pten-/-, Pten-/- p53-/-, Pten-/- Rosa26-ERG, and 3 cell lines derived from GEM models including CaP8, MYC CaP, and MPC3 and normalized to wild-type prostate of litter-mate mice of same genetic background strain

2015-02-20 | E-GEOD-61382 | biostudies-arrayexpress

Identifying actionable targets through integrative analyses of GEM model and human prostate cancer profiling (Illumina)

Project description:Here we profile prostate cancers derived from GEM models of prostate cancer representative of human prostate cancer Total RNA was isolated from established prostate cancers in 3 GEM models of prostate cancer - PB-MYC, Pten-/-, Pten-/- p53-/-

2015-02-20 | E-GEOD-61379 | biostudies-arrayexpress

NSD2 is an actionable driver of prostate cancer metastasis

Project description:NSD2 is an actionable driver of prostate cancer metastasis

| PRJNA487359 | ENA

Transcription profiling by array of human benign prostate, primary and metastatic prostate cancer samples to reveal signatures of metastatic progression

Project description:An integrative analysis of this compendium of proteomic alterations and transcriptomic data was performed revealing only 48-64% concordance between protein and transcript levels. Importantly, differential proteomic alterations between metastatic and clinically localized prostate cancer that mapped concordantly to gene transcripts served as predictors of clinical outcome in prostate cancer as well as other solid tumors. Keywords: prostate cancer progression 13 individual benign prostate, primary and metastatic prostate cancer samples and 6 pooled samples from benign,primary or metastatic prostate cancer tissues.

2005-09-20 | E-GEOD-3325 | biostudies-arrayexpress

Identifying actionable targets through integrative analyses of GEM model and human prostate cancer profiling [Agilent]

Project description:Here we prolife prostate cancers derived from GEM models of prostate cancer representative of human prostate cancer

2015-02-20 | GSE61382 | GEO